Chair Medicinal Cannabis Industry Australia
CEO Cann Group
Peter is an experienced public company senior manager with deep knowledge and expertise in marketing and technology development. Since joining Cann Group in May 2016, Peter has reset the business plan as directed by the board and led the company through a successful initial public offering (IPO) to list on the Australian Securities Exchange (ASX), raising $13.5 million while bringing outstanding institutional and cornerstone investor support. This was followed by a subsequent $70m+ capital raising within the same year to accelerate the company’s expansion program. In a 28-year career at Nufarm Limited (ASX: NUF), Peter held senior management roles in marketing, business development, and information technology and led Nufarm’s new technologies division which involved the licensing and commercial development of several new agribusiness technologies. He has project managed the successful integration of newly acquired businesses and has extensive experience working with regulators in Australia and overseas.
CEO & Executive Director Cronos Australia
Before founding Cronos Australia, Rodney was a consultant with The Boston Consulting Group, later taking up a senior role at an Australian multinational before co-founding NewSouthern Capital. He heads up the capital raising and portfolio company teams at NewSouthern, and sits on the investment, audit and risk committee for the company. As a graduate of the Royal Military College, Duntroon, Rodney commenced his career as an Australian Army infantry officer and was also a senior member of the UK Government’s Counter Narcotics team at The British Embassy in Kabul, which was responsible for targeting the massive opium and cannabis cultivation and trafficking issue in Afghanistan. Rodney holds a Bachelor of Commerce, Bachelor of Laws, MBA (Wharton, University of Pennsylvania), and an MPA (Harvard University). He is an admitted lawyer to the Supreme Court of New South Wales, a Graduate of the Australian Institute of Company Directors, and an Authorised Representative under an Australian Financial Services License. Rodney was also named the Victorian Australian of the Year in 2005.
Group CEO THC Global Group
Ken is a veteran of multiple biotech and pharmaceutical companies over the past three decades as CEO, Managing Director and Chairman. In previous Executive roles Ken has had full P&L and balance sheet responsibility including legal and financial compliance in listed and international structures, leading businesses with revenue exceeding $200m and asset bases within $100m – $500m. Ken has a proven track record in hands on roles within major listed international companies improving profit growth and effecting share price increase.
Ken was involved in various senior levels within THC since prior to listing on the ASX, Ken has been instrumental in the execution of the Company’s strategic plan, including the acquisition of THC’s manufacturing facility and the securing of commercial partnerships with Ascent Industries (North America) and Endoca (Europe). Ken has a specific mandate to drive future acquisitions and alliances for THC.
Executive Chairman & CEO MedReleaf Australia
Russell co-founded MedReleaf Australia with Nathan Davis in 2016 as a privately owned medicinal cannabis company.
He has 35 years success in pharmacy business ownership, management and innovation combined with experience in a number of other fields including pharmacy wholesaling to an 80 member group of pharmacist proprietors, property development, business mentoring, medical centre management and semi-professional sports coaching as an accredited AFLQ senior coach.
Dr Paul MacLeman
Executive Director AusCann Group Holdings Ltd
MBA. BVSc. Grad Dip Tech Mgt. Grad Cert Eng. Grad ADIC
Dr MacLeman has over 25 years’ board and executive experience across the life sciences, agricultural and not for profit sectors. This includes strategy formulation, capital raising, business development, technology commercialisation and sales & marketing. He has also launched a variety of products in Australia, the US and Asia, founded life sciences start-ups in the biologics area and worked in investment banking. Dr MacLeman is currently Chair of AdAlta Limited, Livac Pty Limited, and is a Non-Executive Director of Sypharma Pty Limited. He Chairs the committee reviewing the National Vocational Education Training Package in Pharmaceuticals and has in the past Chaired the Committee to develop a nationally recognised Course in Pharmaceutical Manufacture for Victoria, the AusBiotech Agricultural Advisory Board and has been Managing Director of Nasdaq, ASX and TSX listed companies.